{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MSESOP-2009 MSE Tuberculin skin testing (mantoux) for health care workers 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "TUBERCULIN SKIN TESTING (MANTOUX) FOR HEALTH CARE WORKERS"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MSESOP-2009"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP/CCP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "Occupational Health staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "19 October 2020"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "18 October 2023"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "National Guidance/Recommendations NICE (2019) Tuberculosis NG33 DOH (2013) Immunisation against infectious diseases \u2013 The Green Book (TB chapter 32 updated 2018)"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "12"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "HR/ Occupational Health"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Teresa Dowdeswell, Occupational Health Advisor/ Site Lead, Southend"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "MSE NHS Foundation Trust Basildon Hospital Broomfield Hospital Southend Hospital Other (please state) \u2013 external contracts as required"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Site Lead Nurses Group (OH)"
                    },
                    {
                        "text": "14 September 2020"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Kelly McClenaghan, Interim AD Head of Occupational Health and Wellbeing"
                    },
                    {
                        "text": "14 September 2020"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "06 October 2020"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group)"
                    },
                    {
                        "text": "September 20"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "\u2612Trust Intranet \u2610Internet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MSESOP-2009 MSE Tuberculin skin testing (mantoux) for health care workers 1.0.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 6,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Consulted With: this must include Pharmacy if the document has any reference to medication"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Kelly McClenaghan, Angela Hyman"
                    },
                    {
                        "text": "Site Leads, OH"
                    },
                    {
                        "text": "11 August 2020"
                    },
                    {
                        "text": "Emma Dowling"
                    },
                    {
                        "text": "Infection Control Lead"
                    },
                    {
                        "text": "24 August 2020"
                    },
                    {
                        "text": "Simon Worrell"
                    },
                    {
                        "text": "Pharmacy"
                    },
                    {
                        "text": "24 August 2020"
                    },
                    {
                        "text": "Dr Leighton"
                    },
                    {
                        "text": "Occupational Health Physician"
                    },
                    {
                        "text": "24 August 2020"
                    },
                    {
                        "text": "Jenny Keane"
                    },
                    {
                        "text": "TB Nurse Specialist"
                    },
                    {
                        "text": "24 August 2020"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "Staff Screening and Immunisation Policy Infection Control Policy SOP for administration of BCG Vaccine for Health Care Workers TB Policy"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Teresa Dowdeswell"
                    },
                    {
                        "text": "New SOP"
                    },
                    {
                        "text": "19 October 2020"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Contents"
            },
            "type": "ListItem",
            "sequence_num": 7
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "Introduction ................................................................................................................... 4"
            },
            "type": "ListItem",
            "sequence_num": 8
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.0,
                "text": "Scope ........................................................................................................................... 4"
            },
            "type": "ListItem",
            "sequence_num": 9
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Definitions ..................................................................................................................... 4"
            },
            "type": "ListItem",
            "sequence_num": 10
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Key Elements of Policy / Guideline ............................................................................... 4"
            },
            "type": "ListItem",
            "sequence_num": 11
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.0,
                "text": "Training Requirements ................................................................................................. 9"
            },
            "type": "ListItem",
            "sequence_num": 12
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": "Monitoring and Audit ..................................................................................................... 9"
            },
            "type": "ListItem",
            "sequence_num": 13
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.0,
                "text": "Approval and Implementation ....................................................................................... 9"
            },
            "type": "ListItem",
            "sequence_num": 14
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 8.0,
                "text": "Equality Impact Assessment ....................................................................................... 10"
            },
            "type": "ListItem",
            "sequence_num": 15
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 9.0,
                "text": "References ................................................................................................................. 10 Appendix 1: Preliminary Equality Analysis ......................................................................... 11"
            },
            "type": "ListItem",
            "sequence_num": 16
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Introduction"
            },
            "type": "ListItem",
            "sequence_num": 17
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "The tuberculin skin test (Mantoux) is used as a screening test for tuberculosis infection or disease and is an aid to diagnosis. It is used to determine the immune status of employees who require the BCG vaccination."
            },
            "type": "ListItem",
            "sequence_num": 18
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "SSI Tuberculin PPD 2TU/0.1ml is only available in the UK as an unlicensed import. It does not hold a UK Marketing Authorisation and therefore it is unlicensed for use within  the  UK.  SSI  Tuberculin  PPD  2TU/0.1ml  is  a  Prescription-only  Medicine (PoM). This product cannot be administered using Written Orders and must be administered on the basis of a Patient Specific Direction (PSD). A PSD is a written instruction by an independent prescriber for drugs and vaccines to be administered to a named patient after the prescriber has assessed the patient on an individual basis.  The  PSD  will  include  the  dose,  route  and  frequency  of  the  drug  to  be administered to a named patient."
            },
            "type": "ListItem",
            "sequence_num": 19
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.3,
                "text": "The Mantoux test must be carried out prior to BCG vaccination in all clients. The Mantoux  test  is  an  intradermal  diagnostic  test  for  hyposensitivity  to  Tuberculin Purified Protein Derivative which determines eligibility for BCG vaccination."
            },
            "type": "ListItem",
            "sequence_num": 20
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Scope"
            },
            "type": "ListItem",
            "sequence_num": 21
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "The purpose of this document is to:"
            },
            "type": "ListItem",
            "sequence_num": 22
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Provide clarification on HCW's eligible for Mantoux test and BCG vaccination"
            },
            "type": "ListItem",
            "sequence_num": 23
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Outline procedures for vaccinators to follow."
            },
            "type": "ListItem",
            "sequence_num": 24
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Definitions"
            },
            "type": "ListItem",
            "sequence_num": 25
        },
        {
            "type": "table",
            "sequence_num": 26,
            "data": {
                "num_rows": 5,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "TERM"
                    },
                    {
                        "text": "DEFINITION"
                    },
                    {
                        "text": "BCG"
                    },
                    {
                        "text": "Bacille de Calmette et Guerin (BCG) vaccination."
                    },
                    {
                        "text": "HCW"
                    },
                    {
                        "text": "Health Care Workers"
                    },
                    {
                        "text": "OH"
                    },
                    {
                        "text": "Occupational Health"
                    },
                    {
                        "text": "TB"
                    },
                    {
                        "text": "Tuberculosis"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Key Elements of Policy / Guideline"
            },
            "type": "ListItem",
            "sequence_num": 27
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "Prior to Vaccination \u2013Mantoux testing should only be performed on individuals without a BCG scar, with no evidence of a previous BCG vaccination. If there is a documented  positive  T  spot  or  equivalent  test,  the  Mantoux  should  not  be performed."
            },
            "type": "ListItem",
            "sequence_num": 28
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "Recommended Groups for Vaccination \u2013 A list of clients who are eligible for the BCG should be provided on a Patient Specific Directive form to the Occupational Health Physician (OHP) for signature a week before the clinic. This is organised by the admin team in conjunction with the Immunisation Nurse. Additional clients can only be added to the clinic if there is a Patient Specific Directive form signed by the OHP in advance. Appropriate clients will be invited to attend the Occupational Health department. They will be advised that they must attend the 2 appointments."
            },
            "type": "ListItem",
            "sequence_num": 29
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.3,
                "text": "Skin Testing Process"
            },
            "type": "ListItem",
            "sequence_num": 30
        },
        {
            "type": "table",
            "sequence_num": 31,
            "data": {
                "num_rows": 7,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Tuberculin"
                    },
                    {
                        "text": "SSI Tuberculin PPD 2TU/0.1ml is only available in the UK as an unlicensed import. It does not hold a UK Marketing Authorisation and therefore it is unlicensed for use within the UK. SSI Tuberculin PPD 2TU/0.1ml is a Prescription-only Medicine (PoM)."
                    },
                    {
                        "text": "Storage"
                    },
                    {
                        "text": "SSI Tuberculin PPD 2TU/0.1ml must be stored in the original packaging and kept refrigerated at all times between 2-8 degrees Celsius"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "for further advice."
                    },
                    {
                        "text": "Precautions"
                    },
                    {
                        "text": "Any acute infectious illness; in this case the administration may need to be postponed. If the client is unwell, pyrexial, has diarrhoea or vomiting, or is lethargic, a doctor should be consulted prior to administering the Mantoux skin test. Individuals who have been on antibiotics for an acute infection should have completed the course 48 hours prior to the Mantoux test being carried out"
                    },
                    {
                        "text": "The reaction to tuberculin protein may be suppressed by the following: glandular fever viral infections such as measles and varicella zoster (chicken pox), but NOT upper respiratory tract infections or gastroenteritis live viral vaccines (tuberculin testing should not be carried out within four weeks of having received a live viral vaccine) sarcoidosis corticosteroid therapy immunosuppression due to disease or treatment, including HIV infection"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 32,
            "data": {
                "num_rows": 10,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "Individuals who have a negative test but who may have had a significant infection (such as measles, varicella zoster (chicken pox), scarlet fever, glandular fever) at the time of testing or at the time of reading should be re-tested two to three weeks after clinical recovery before being given BCG as appropriate. If a second test is necessary it should be carried out on the other arm as repeat testing at one site may alter the reactivity either by hypo - or, more often, hyper- sensitising the skin and a changed response may reflect local changes in skin sensitivity only."
                    },
                    {
                        "text": "Administration"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "SSI Tuberculin PPD 2TU/0.1ml information leaflet after care instructions anaphylactic pack 1ml graduated syringe or tuberculin syringe 26G 10mm (0.45mm x 10mm)short bevelled needle for intradermal injection Sharps bin"
                    },
                    {
                        "text": "Obtain verbal consent and ensure that the patient is able to return in 48-72 hours for Mantoux reading"
                    },
                    {
                        "text": "Prepare the syringe by drawing up 0.1ml of SSI Tuberculin PPD 2TU/0.1ml and attach a 26g needle"
                    },
                    {
                        "text": "Position the patient by placing the forearm palm side up on a firm, well lit surface. Locate an area of healthy skin 5 to 10 centimetres below the elbow joint which is free of muscle margin, hair, veins, sores or scars"
                    },
                    {
                        "text": "Skin cleansing is not indicated unless the skin is visibly dirty"
                    },
                    {
                        "text": "Stretch the selected area of skin between the thumb and forefinger. The needle should be inserted slowly with the bevel upwards at an angle of 5 to 15 degrees. Advance the needle through the epidermis approximately 3mm so the bevel is visible just under the skin. Whilst holding the syringe in place on the forearm the tuberculin solution should be slowly injected. If the needle is inserted correctly you should feel quite firm resistance as the tuberculin enters the skin to form a tense pale bleb of typically 7 mm in diameter."
                    },
                    {
                        "text": "Intradermal Administration"
                    },
                    {
                        "text": "The intradermal technique is the most accurate method of administration because the dose can be measured precisely and the administration can be controlled , it also ensures that adverse"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 33,
            "data": {
                "num_rows": 7,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "reactions are minimised The type of syringe and needle size is important to ensure correct administration of the intradermal injection (jet injectors and multiple puncture devices should not be used)"
                    },
                    {
                        "text": "Intradermal technique"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "If the bleb is less than 6mm in diameter or does not appear to be tense then the test should be repeated on the opposite arm or at least 5cm away from the original site. It is essential that the test is performed correctly to ensure an accurate reading."
                    },
                    {
                        "text": "Mantoux tests can be undertaken at the same time as inactivated vaccines are administered. Live viral vaccines can suppress the tuberculin response, and therefore testing should not be carried out within four weeks of having received an injectable live viral"
                    },
                    {
                        "text": "Aftercare"
                    },
                    {
                        "text": "Clients should be advised to wash the site normally. Do not cover Do not apply perfumes/lotions to the site To try not to scratch the site if it becomes itchy"
                    },
                    {
                        "text": "Reading the Mantoux Test"
                    },
                    {
                        "text": "The test must be read in accordance with the guidance from the Green Book, 48-72 hours following administration, but a valid reading can usually be obtained up to 96 hours later"
                    },
                    {
                        "text": "The transverse diameter of the area of induration at the injection site is measured with a ruler and the result recorded in millimetres. As several factors affect interpretation of the test, the size of the induration should be recorded and NOT just as a negative or positive result. The area of erythema is irrelevant."
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 34,
            "data": {
                "num_rows": 5,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "Diameter of induration"
                    },
                    {
                        "text": "Interpretation"
                    },
                    {
                        "text": "Action"
                    },
                    {
                        "text": "Less than 5mm"
                    },
                    {
                        "text": "Negative \u2013 no significant hypersensitivity to tuberculin protein"
                    },
                    {
                        "text": "Previously unvaccinated individuals may be given BCG provided there are no contraindications"
                    },
                    {
                        "text": "5mm or greater *"
                    },
                    {
                        "text": "Positive \u2013 hypersensitive to tuberculin protein"
                    },
                    {
                        "text": "BCG vaccination should not be given The individual should be referred for further investigation in line with NICE guidance"
                    },
                    {
                        "text": "*Prior BCG may lead to a weakly positive tuberculin skin test result. However, economic modelling by NICE suggests that the treatment for latent TB of all Mantoux tests positive individuals irrespective of prior BCG is cost effective. For the purpose of assessing whether an individual might benefit from a BCG vaccine, a positive Mantoux test or interferon gamma release assay (IGRA) indicating prior sensitization is an indication not to administer BCG, whole a negative IGRA should not be used as the sole basis for a decision to give BCG. In the absence of a Mantoux test, persons with a negative IGRA result should only be given a BCG in the absence of a documented record of prior BCG, a BCG scare or reliable history of BCG vaccination."
                    },
                    {
                        "text": "Documentation"
                    },
                    {
                        "text": "Client cohort record to state: Due date Date of administration Dose Batch number Method of administration (ie intradermal) Site of administration Size of bleb Consent obtained Consent type Contraindication to vaccine (yes/no) Employment Type of employment (i.e. current) Name of administering nurse"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 35,
            "data": {
                "num_rows": 4,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": "The PSD should be kept in line with the Record Retention SOP."
                    },
                    {
                        "text": "Adverse effects"
                    },
                    {
                        "text": "Common: pain, irritation or discomfort at the injection site immediately after the injection. Uncommon: headache, fever or enlargement of regional lymph nodes."
                    },
                    {
                        "text": "Rare: vesiculation, skin necrosis and urticaria."
                    },
                    {
                        "text": "Very rare: hypersensitivity including anaphylactic reactions."
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Training Requirements"
            },
            "type": "ListItem",
            "sequence_num": 36
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "Staff should complete the on line immunisation training (PHE) on Mantoux testing and  BCG  and  provide  certificate  of  completion.  Should  shadow  a  competent practitioner."
            },
            "type": "ListItem",
            "sequence_num": 37
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.2,
                "text": "Staff  should  be  deemed  competent  by  their  Site  Lead  following  competency assessment."
            },
            "type": "ListItem",
            "sequence_num": 38
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Monitoring and Audit"
            },
            "type": "ListItem",
            "sequence_num": 39
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "Outlined  below  is  the  Trust's  process  of  monitoring  compliance  with,  and  the effectiveness of the document's main points."
            },
            "type": "ListItem",
            "sequence_num": 40
        },
        {
            "type": "table",
            "sequence_num": 41,
            "data": {
                "num_rows": 2,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Aspect of compliance or effectiveness being monitored"
                    },
                    {
                        "text": "Monitoring Method"
                    },
                    {
                        "text": "Individual department responsible for the monitoring"
                    },
                    {
                        "text": "Frequency of the monitoring activity"
                    },
                    {
                        "text": "Group / Committee / forum which will receive the findings/monitoring report"
                    },
                    {
                        "text": "Committee / individual responsible for ensuring the actions are completed"
                    },
                    {
                        "text": "Compliance to vaccination"
                    },
                    {
                        "text": "Audit"
                    },
                    {
                        "text": "OH"
                    },
                    {
                        "text": "6 monthly"
                    },
                    {
                        "text": "Occupational Health Group Managers of relevant departments"
                    },
                    {
                        "text": "AD for Occupational Health and Wellbeing"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Approval and Implementation"
            },
            "type": "ListItem",
            "sequence_num": 42
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "All policies, procedures and guidelines will be approved by the senior nurse group within OH , which is the specialist group with the authority to approve local standard operating procedures. These will then be forwarded to the Document control team for submission and ratification by the Joint Document Management Group."
            },
            "type": "ListItem",
            "sequence_num": 43
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.2,
                "text": "It is the author's responsibility to inform the Associate Director of Occupational Health and Wellbeing and OH team of the approved policy documents when they are uploaded to the Trust's Intranets."
            },
            "type": "ListItem",
            "sequence_num": 44
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Equality Impact Assessment"
            },
            "type": "ListItem",
            "sequence_num": 45
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "The Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals."
            },
            "type": "ListItem",
            "sequence_num": 46
        },
        {
            "data": {
                "is_heading": 0,
                "text": "(Refer to appendix 1)"
            },
            "type": "ListItem",
            "sequence_num": 47
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "References"
            },
            "type": "ListItem",
            "sequence_num": 48
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Department of Health (2013) Immunisation Against Infectious Diseases. Available from: https://www.gov.uk/government/collections/immunisation-against-infectious- disease-the-green-book"
            },
            "type": "ListItem",
            "sequence_num": 49
        },
        {
            "data": {
                "is_heading": 0,
                "text": "NICE (2019) Tuberculosis (NG33)Available from: https://www.nice.org.uk/guidance/ng33/chapter/Recommendations#preventing-tb"
            },
            "type": "ListItem",
            "sequence_num": 50
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Public Health England/ Royal College of Nursing (2018) National Minimum standards and core curriculum for immunisation training for registered health practitioners. Available from: https://www.gov.uk/government/publications/national- minimum-standards-and-core-curriculum-for-immunisation-training-for-registered- healthcare-practitioners"
            },
            "type": "ListItem",
            "sequence_num": 51
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Tuberculin skin testing (mantoux) for health care workers / MSESOP-2009 /1.0"
            },
            "type": "ListItem",
            "sequence_num": 52
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 53
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Tuberculin skin testing (mantoux) for health care workers / MSESOP-2009 /1.0"
            },
            "type": "ListItem",
            "sequence_num": 54
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Preliminary Equality Analysis"
            },
            "type": "ListItem",
            "sequence_num": 55
        },
        {
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to Tuberculin skin testing (mantoux) for health care workers / MSESOP-2009: (please tick all that apply)"
            },
            "type": "ListItem",
            "sequence_num": 56
        },
        {
            "type": "table",
            "sequence_num": 57,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": "A change to an existing document"
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": "A new document"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 58,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "1."
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Administration of Mantoux skin test using an unlicenced product."
                    },
                    {
                        "text": "2."
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "To afford protection to staff who are exposed to TB"
                    },
                    {
                        "text": "3."
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Staff are protected from TB."
                    },
                    {
                        "text": "4."
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "5."
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change?"
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "b) If so, with whom?"
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 59,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Preliminary analysis completed by:"
                    },
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Teresa Dowdeswell"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Occupational Health Advisor Site Lead Southend"
                    },
                    {
                        "text": "24 August 2020"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "If you have identified any negative impact in the preliminary analysis above, please request and complete the full Equality Impact Assessment (EIA) from Document Control."
            },
            "type": "ListItem",
            "sequence_num": 60
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 61
        }
    ]
}